StockData

Lexicon Pharmaceuticals vs Scilex

LXRX and SCLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LXRX and SCLX compare

Lexicon Pharmaceuticals is the larger company, worth 75 times as much as Scilex ($792M against $10.6M).

Scilex grew revenue faster over the last twelve months (−28.5% versus −29.0% for Lexicon Pharmaceuticals).

Lexicon Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −147% compared with −1470% at Scilex.

Lexicon Pharmaceuticals scores higher on the StockData Score (5 against 1 for Scilex), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLXRXSCLX
Size and price
Market cap$792M$10.6M
Share price$1.78$1.25
Change, 1 year19.5%−93.0%
Change, 5 years−62.4%−99.6%
Beta (5Y)0.012.18
Employees8134
StockData Score
Total score5 (better)1
Valuation score01 (better)
Growth score1 (better)0
Performance score2 (better)0
Health score2 (better)0
Dividend score00
Valuation
P/S19.1×0.3× (better)
P/B4.5×–
Fair value$0.950–
Margin of safety−87.4%–
Growth
Revenue growth (TTM)−29.0%−28.5% (better)
Revenue growth, 5Y average15.7% (better)5.1%
Profitability
Gross margin99.1%161% (better)
Operating margin−131% (better)−1136%
Net margin−147% (better)−1470%
Return on equity−40.2%–
Return on invested capital−163%–
Financial health
Debt / equity0.29–
Interest coverage–−22.2×
Current ratio13.37 (better)0.07
Altman Z-score−4.87 (better)−12.75
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions81.9%9.8%
Insider net buying, 12 months$2.8M (better)−$12.8M

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.